Cash-flow scrutiny reaches Sundrug stock at JPY 3,656

Published on 10/25/2026 at 02:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Yahoo Finance flagged cash-flow valuation pressure for Sundrug on October 19, 2026. Sundrug stock closed at JPY 3,656 in Tokyo on October 23, 2026.

Cash flow and valuation pressure

Cash flow analysis questioned Sundrug's valuation on October 19, 2026.
First-quarter revenue reached JPY 215.33 billion against JPY 207.70 billion a year earlier.
Sundrug stock closed at JPY 3,656 in Tokyo on October 23, 2026.
Market capitalization stood at JPY 427.7 billion on October 23, 2026.

Sundrug, JP3336600006, Illustration mit AI erstellt.

Cash-flow scrutiny reached Sundrug Co. (ISIN JP3336600006) after a valuation analysis highlighted a gap between projected free cash flow and the share price. Yahoo Finance published the assessment on October 19, 2026, while the stock later closed at JPY 3,656 in Tokyo on October 23, 2026.

Cash flow meets the share price

The analysis put last-twelve-month free cash flow at JPY 7.36 billion and argued that projected future cash generation did not fully support the prevailing valuation. It also cited a five-year share-price gain of 22.90 percent, making cash conversion a more important test for the current market value.

The valuation discussion does not erase Sundrug's operating growth. For the first quarter ended June 30, 2026, revenue was JPY 215.33 billion, compared with JPY 207.70 billion in the year-earlier quarter, a 3.67 percent increase, according to Moomoo.

What does the target imply?

Markets Insider reported on October 6, 2026, that UBS maintained a Hold rating and a JPY 3,820 price target. Against the October 23 Tokyo close, that target was 4.49 percent higher, but the valuation case remains tied to the pace at which earnings become cash.

Three dates frame the story

On September 9, 2026, first-quarter figures showed revenue of JPY 215.33 billion and operating profit of JPY 12.09 billion, as reported in the Moomoo news flow. On October 6, 2026, UBS kept its JPY 3,820 target. On October 19, 2026, Yahoo Finance assessed the shares against JPY 7.36 billion of last-twelve-month free cash flow.

Next reporting date is November 13

TradingView lists November 13, 2026, as Sundrug's next earnings-report date. The next release will show whether revenue growth and cash generation are moving together.

Tokyo valuation remains the test

Sundrug's market capitalization was JPY 427.7 billion on October 23, 2026, while its 52-week range was JPY 3,506.00 to JPY 4,466.00. The further course of trading can be followed through the Tokyo market data for Sundrug stock.